USPTO serial 79450596
ZEYDOVIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- PEISECKI, MARK A
- Law office
- TMEG LAW OFFICE 105
What this means
Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose. Watch for publication (status 686) and monitor the 30-day opposition window.
Need help with ZEYDOVIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Miriam D. Trudell
Miriam D. Trudell Davis Graham & Stubbs LLP3400 Walnut Street, Suite 700Denver, CO 80205United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical preparations, namely, for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); pharmaceutical preparations, namely, for treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia; medical preparations for the treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia | ACTIVE | — |
| 010 | Medical devices for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders, namely, short bowel syndrome (SBS) in humans by introducing pharmaceutical preparations, and parts and fittings therefor; medical devices for treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia, by introducing pharmaceutical preparations, and parts and fittings therefor | ACTIVE | — |
| 044 | Medical services, namely, treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS) and pharmaceutical services, namely, treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical and pharmaceutical advice in the field of treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, short bowel syndrome (SBS); medical services, namely, treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia and pharmaceutical services, namely, treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from Congenital HyperInsulinism (CHI) and hypoglycemia | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 7, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 7, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 7, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 7, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 7, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 6, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 5, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 5, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 23, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 23, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 26, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 25, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 3, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 2, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 28, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |